ABBV ABBV アッヴィ

 ABBVのチャート


 ABBVの企業情報

symbol ABBV
会社名 AbbVie Inc (ABBV アッヴィ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス(HCV)とヒト免疫不全ウイルス(HIV)を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA(アダリムマブ)、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa(カルビドパおよびレボドパ)、麻酔薬およびZINBRYTA(ダクリズマブ)を含む他の製品を提供する。  アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬「ヒュミラ」など。本社はイリノイ州ノ―ス・シカゴ。  AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
本社所在地 847 932-7900
代表者氏名 Richard A. Gonzalez
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 847-932-7900
設立年月日 41000
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 30000人
url www.abbvie.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 9148.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 119125.30000
売上高 売上高(百万ドル) 32753.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151374.30000
当期純利益 当期純利益(百万ドル) 5743.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling.

 ABBVのテクニカル分析


 ABBVのニュース

   Dry Eye Disease Market Clinical Analysis, Growth, Research Outlook and Forecast 2026| Horus Pharma, Johnson & Johnson, AbbVie Inc, Alcon Inc.  2021/09/05 14:19:09 OpenPR
The Global Dry Eye Disease Market Research Report 2021-2026 is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews
   Absolute Shares Trust Buys Gilead Sciences Inc, Pfizer Inc, Altria Group Inc, Sells AT&T ...  2021/09/03 17:38:02 GuruFocus
Related Stocks: IP , PFG , UNM , ABBV , BGS , XRX , GILD , PFE , MO , DOW , KHC , SO , PM , SXC , IBM , ETD , VGR , SWM , T , STX , LYB , LUMN , HRB , PBCT ,
   Cell-Based Immunotherapy Market 2021 Emerging Developments, Rising Growth and Increasing Immense Opportunities Till 2028 | AbbVie Inc., Genentech USA, Inc., Amgen Inc, Bayer AG, Boehringer Ingelheim International GmbH & More  2021/09/03 16:18:45 OpenPR
The proposed Cell-Based Immunotherapy Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed
   Medical Aesthetics Market to Record $ 7.64 bn Growth | Top Vendors Including 3M Co. and AbbVie Inc. Will Change Market Dynamics in Life Sciences Tools & Services Industry | Technavio  2021/09/03 05:00:00 Benzinga
NEW YORK , Sept. 3, 2021 /PRNewswire/ -- The " Medical Aesthetics Market by Type and Geography - Forecast and Analysis 2020-2024 " report has been added to Technavio''s offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years. The potential growth difference for the Medical Aesthetics Market between 2020 and 2024 is USD 7.64 billion . To get the exact yearly growth variance and the Y-O-Y growth rate, Full story available on Benzinga.com
   ABBV Stock: The FDA Blow That Just Sent AbbVie Tumbling on Wednesday  2021/09/01 20:01:55 InvestorPlace
Here''s the big FDA-related news today that''s sparking a sharp selloff of pharmaceutical giant AbbVie and ABBV stock.
   FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes  2021/07/21 05:00:00 Intrado Digital Media
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the revised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells. 2 This can lead to weakness, frequent infections, anaemia and debilitating fatigue. 3 In some cases, MDS can also progress into acute myeloid leukaemia (AML). 4,5 Every year in the US, approximately 10,000 people are diagnosed with MDS, and the median survival for those with higher-risk MDS is approximately 18 months. 1,3 Higher-risk MDS is associated with poor prognosis, reduced quality of life, and limited treatment options, said Levi Garraway, M.D., Ph.D., Roches Chief Medical Officer and Head of Global Product Development. We are pleased that the FDA has granted Venclexta its sixth Breakthrough Therapy Designation in recognition of its potential to improve outcomes for people with MDS in combination with azacitidine. This designation was granted based on interim results from the phase Ib M15-531 study investigating Venclexta/Venclyxto plus azacitidine in people with previously untreated, higher-risk MDS.
   Drug distributors settle New York opioid claims for up to $1.18bn  2021/07/20 20:51:40 Business Recorder
NEW YORK: The three largest U.S. drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the states attorney general said on Tuesday. McKesson Corp, Cardinal Health Inc and AmerisourceBergen Corp settled as state attorneys general prepare to announce as soon as this week a landmark $26 billion deal with the distributors and drugmaker Johnson & Johnson resolving cases nationwide. The deal with New York Attorney General Letitia James and the populous Long Island counties of Nassau and Suffolk came three weeks into the first jury trial accusing companies of profiting from a flood of addictive painkillers that devastated communities. While no amount of money will ever compensate for the millions of addictions, the hundreds of thousands of deaths, or the countless communities decimated by opioids, this money will be vital in preventing any future devastation, James said.
   Coho Partners, Ltd. Buys Perrigo Co PLC, RPM International Inc, Amazon. ...  2021/07/20 18:38:13 GuruFocus
Related Stocks: PRGO , RPM , AAPL , MSFT , AMZN , GOOG , NVDA , EPD , AXP , ABBV , CRI , BRK.A ,
   Carnick & Kubik Group, LLC Buys Microsoft Corp, Apple Inc, Lam Research Corp, Sells iShares ...  2021/07/20 12:38:06 GuruFocus
Related Stocks: MSFT , AAPL , LRCX , XLV , ABBV , TGT , SCHW , URI , FDX , VOX , GM , DELL , XLP , NVS , VRTX , IAU , TBF , IEMG ,
   Manning & Napier Group, Llc Buys Canadian National Railway Co, Amazon. ...  2021/07/19 20:38:13 GuruFocus
Related Stocks: CNI , AMZN , MCO , CRM , NEM , CMCSA , PG , H , VZ , WAB , NOC , ADBE , BABA , TXN , PFE , ABBV , WFC , ACN ,
   Denture Fixative Market is Booming Worldwide | Novartis, Janssen Biotech, AbbVie, Biogen  2021/07/17 20:43:23 Tramways Monthly
The latest study released on the Global Denture Fixative Market by AMA Research evaluates market size, trend, and forecast to 2026. The Denture Fixative market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help []
   Shikiar Asset Management Inc Buys MGM Resorts International, LVMH Moet Hennessy Louis Vuitton ...  2021/07/16 22:38:06 GuruFocus
Related Stocks: AMD , TOL , ZS , NYCB , DEA , VRT , MGM , LVMUY , CARR , AGR , SO , ABBV , TDOC , GSPN.PFD , KKRPA.PFD , DM , GOEV , VIAC ,
   Blustering Stock Grabbing Investors Attention: Fiserv, Inc. (NASDAQ:FISV), AbbVie Inc. (NYSE:ABBV)  2021/07/16 22:09:14 Stock Equity
Fiserv, Inc. (NASDAQ:FISV) with the stream of 0.93% also noticed, India AbbVie Inc. (NYSE:ABBV) encountered a rapid change of 0.47% in the last hour of Fridays trading session. Fiserv, Inc. The post Blustering Stock Grabbing Investors Attention: Fiserv, Inc. (NASDAQ:FISV), AbbVie Inc. (NYSE:ABBV) appeared first on Stocks Equity .
   AbbVie provides regulatory update on RINVOQ sNDA  2021/07/16 12:39:41 Seeking Alpha
   Huge Demand of Rheumatoid Arthritis (RA) Drugs Market by 2027 | AbbVie, Roche, Merck  2021/07/15 18:35:43 Tramways Monthly
Rheumatoid Arthritis (RA) Drugs Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in []

 関連キーワード  (医薬品 米国株 ABBV アッヴィ ABBV )

 twitter  (公式ツイッターやCEOツイッターなど)